Quick Answer
CNS Pharmaceuticals, Inc. reported Total Assets of $8.62 million for fiscal year 2025.
CNS Pharmaceuticals, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $8.62M | -0.9% |
| 2024 | $8.70M | +411.6% |
| 2023 | $1.70M | -87.0% |
| 2022 | $13.05M | +49.1% |
| 2021 | $8.76M | -44.8% |
| 2020 | $15.85M | +100.4% |
| 2019 | $7.91M | +1057.9% |
| 2018 | $683.3K | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.87M | +60.2% | -18.2% |
| June 30, 2025 | $14.51M | +487.5% | +5.5% |
| March 31, 2025 | $13.75M | +727.8% | +58.0% |
| December 31, 2024 | $8.70M | +411.6% | +17.4% |
| September 30, 2024 | $7.41M | +218.3% | +200.1% |
| June 30, 2024 | $2.47M | -61.7% | +48.7% |
| March 31, 2024 | $1.66M | -77.6% | -2.4% |
| December 31, 2023 | $1.70M | -87.0% | -26.9% |
- CNS Pharmaceuticals, Inc. showed a decrease of -0.9% in Total Assets compared to the prior fiscal year.
- Over the 2018–2025 period, CNS Pharmaceuticals, Inc.’s total assets has grown by 1162.0% (from $683.3 thousand to $8.62 million).
- The most recent figure is from CNS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: